FLT3-ITD/NPM1
Purpose
Mutations in FLT3 and NPM1 are commonly seen in acute myeloid leukemia (AML) and information on these mutations is used for therapeutic decision making in AML
CPT Codes
81245, 81310
Methodology
PCR and capillary electrophoresis of DNA obtained from blood, bone marrow, or cell suspensions. At least 30% or greater lesional cells are required for detection. This test should not be ordered for MRD evaluation.
Turnaround Time
5 days
Sample Tested
Blood, bone marrow, cell suspensions and/or extracted DNA.